+

WO2007049914A1 - S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant - Google Patents

S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant Download PDF

Info

Publication number
WO2007049914A1
WO2007049914A1 PCT/KR2006/004369 KR2006004369W WO2007049914A1 WO 2007049914 A1 WO2007049914 A1 WO 2007049914A1 KR 2006004369 W KR2006004369 W KR 2006004369W WO 2007049914 A1 WO2007049914 A1 WO 2007049914A1
Authority
WO
WIPO (PCT)
Prior art keywords
strontium
omeprazole
hydrate
crystalline
mixture
Prior art date
Application number
PCT/KR2006/004369
Other languages
English (en)
Inventor
Tae Hee Ha
Hee Sook Oh
Won Jeoung Kim
Chang Hee Park
Eun Young Kim
Young Hoon Kim
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Priority to AU2006306906A priority Critical patent/AU2006306906B2/en
Priority to BRPI0617879-0A priority patent/BRPI0617879A2/pt
Priority to CN2006800396089A priority patent/CN101296921B/zh
Priority to CA2626085A priority patent/CA2626085C/fr
Priority to NZ568412A priority patent/NZ568412A/en
Priority to JP2008537592A priority patent/JP5017274B2/ja
Publication of WO2007049914A1 publication Critical patent/WO2007049914A1/fr
Priority to IL190709A priority patent/IL190709A/en
Priority to NO20082358A priority patent/NO20082358L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to S-omeprazole strontium or a hydrate thereof having improved optical purity, thermal stability, solubility and non-hygroscopicity, a method for preparing same, and a pharmaceutical composition comprising same.
  • Patent No. 0 005 129 Patent No. 0 005 129
  • Losec ® Commercial formulations
  • Prilosec ® (AstraZeneca AB), are marketed as medicaments for prevention and treatment of gastric acid-related disorders.
  • This omeprazole should be formulated as enteric coated form because it has a structurally neutral molecule and thus it is thermally and chemically unstable under a condition below neutral pH value.
  • omeprazole salts and hydrates thereof e.g., lithium, sodium, potassium, magnesium, calcium, titanium, ammonium, and guanidine salts.
  • Such omeprazole salts are much more stable than omeprazole in the neutral form.
  • Omeprazole is a racemic mixture composed of equal amounts of R- and S-enantiomers.
  • S-omeprazole of formula (III) is much more preferred over the R-isomer in the treatment of gastric or duodenal ulcer, gastroesophageal reflux disease, etc., because the R-isomer tends to be metabolized as inactive metabolites in the irregular variations. Accordingly, there have been many attempts to develop a method for preparing pure S-omeprazole which is substantially free of R-omeprazole.
  • racemic omerprazole has been resolved to isolate the S-isomer by a high performance liquid chromatography (see Erlandsson et al., Journal of Chromatography, 535, 305-319 (1990)), and a process for preparing each of the omeprazole enantiomers is disclosed in PCT Publication No. WO 1992/08716.
  • the separated S-omeprazole products have not been regarded as a stable solid of the pharmaceutically required purity.
  • US patent No. 6,162,816 discloses a crystalline S-omeprazole, but even this crystalline form of S-omeprazole is not sufficiently stable.
  • US Patent Nos. 5,714,504 and 5,693,818 disclose S-omeprazole salts and hydrates thereof, e.g., lithium, sodium, potassium, magnesium, calcium, and ammonium salts.
  • US Patent Nos. 6,369,085 and 6,511,996 disclose the crystalline potassium salt as well as magnesium salt dihydrate and trihydrate of S-omeprazole, together with their polymorphs. These S-omeprazole salts have stability superior to S-omeprazole itself.
  • S-omeprazole salts with sodium, potassium and magnesium, or hydrates thereof are commercially marketed with the trade name Nexium ® (AstraZeneca AB) as a medicament for prevention and treatment of ulcer.
  • the sodium and potassium salts are preferred for injectable administration because of their good solubility, but they are unsuitable for oral administration due to their hygroscopicity.
  • non-hygroscopic S-omeprazole magnesium trihydate is preferred in terms of oral administration of a solid form of omeprazole, but it is not easy to achieve the optical purity required pharmaceutically.
  • S-omeprazole magnesium trihydate has been subjected to the salt exchange with the optically pure sodium or potassium salt prepared in advance to achieve satisfactory therapeutic effects ⁇ see Cotton et al., Tetrahedron Asymmetry, 11, 3819-3825 (2000)).
  • Strontium is an alkaline earth metal of IIA group and it exists in nature in the form of 4 isotopes, 88 Sr (82.58%), 87 Sr (7.00%), 86 Sr (9.86%) and 84 Sr (0.56%). It is also known that strontium exerts no safety problems even at a dose of 633 mg/kg/day in rats ⁇ see P. J. Marie et al., Mineral & Electrolyte Metabolism, 11, 5-13 (1985)). Strontium is reported to be ingested by people in an average amount of about 3.3mg/day per 70 kg body weight during the course of everyday life ⁇ see Report of Toxicological Profile for Strontium, U.S. Department of Health and Human Services, 2004).
  • strontium supports calcium metabolism in bone tissues to promote the bone formation and inhibit the resorption of bone tissues ⁇ see S. P. Nielsen, Bone, 35, 583-588 (2004)).
  • strontium salts which have been pharmaceutically used, strontium ranelate, the salt of strontium with ranelic acid is known.
  • the present inventors have endeavored to develop a novel salt of S-omeprazole and found that S-omeprazole strontium or a hydrate thereof has much improved optical purity, thermo-stability, non-hygroscopicity and solubility over conventional salts.
  • a method for preparing S-omeprazole strontium of formula (I) or a hydrate thereof which comprises the step of adding strontium hydroxide or another strontium salt to a neutral or basic solution containing S-omeprazole and stirring the resulting mixture.
  • a pharmaceutical composition comprising S-omeprazole strontium of formula (I) or a hydrate thereof as an active ingredient and a pharmaceutical acceptable carrier for preventing or treating a gastric acid-related disorder.
  • FIG. 1 an X-ray powder diffraction (XPRD) spectrum of the crystalline S-omeprazole strontium tetrahydrate (Crystalline Form A) obtained according to a preferred embodiment of the present invention in Example 1 ;
  • XPRD X-ray powder diffraction
  • FIG. 2 a differential scanning calorimeter (DSC) curve of the crystalline S-omeprazole strontium tetrahydrate (Crystalline Form A) obtained according to a preferred embodiment of the present invention in Example 1;
  • FIG. 3 an XPRD spectrum of the crystalline S-omeprazole strontium anhydrate (Crystalline Form B) obtained according to another preferred embodiment of the present invention in Example 9;
  • FIG. 4 a DSC curve of the crystalline S-omeprazole strontium anhydrate (Crystalline Form B) obtained according to another preferred embodiment of the present invention in Example 9;
  • FIG. 5 an XPRD spectrum of the crystalline S-omeprazole strontium hydrate (Crystalline Form C) obtained according to still another preferred embodiment of the present invention in Example 10;
  • FIG. 6 a DSC curve of the crystalline S-omeprazole strontium hydrate (Crystalline Form C) obtained according to still another preferred embodiment of the present invention in Example 10;
  • FIG. 7 an XPRD spectrum of the amorphous S-omeprazole strontium obtained according to yet another preferred embodiment of the present invention in Example 11 ;
  • FIG. 8 a DSC curve of the amorphous S-omeprazole strontium obtained according to yet another preferred embodiment of the present invention in Example 11.
  • the inventive S-omeprazole strontium of formula (I) or a hydrate thereof is a novel salt of S-omeprazole, which is optically purer, thermally more stable, less hygroscopic and more soluble than any of the corresponding magnesium salts.
  • the S-omeprazole strontium according to the present invention has two S-omeprazole molecules coordinated to strontium ion (II), to which at least one H 2 O molecule may be coordinated.
  • strontium ion II
  • Such S-omeprazole strontium or a hydrate thereof can be produced in an amorphous form or crystalline form, preferably a crystalline form, which may be confirmed by X-ray powder diffraction (XRD) or differential scanning calorimeter (DSC) analysis.
  • a preferred embodiment of the present invention is the crystalline tetrahydrate of S-omeprazole strontium, represented by formula (IV):
  • the XRD spectrum of the crystalline S-omeprazole strontium tetrahydrate shows major peaks having 1/I 0 values of at least 3% (I is the 5 intensity of each peak; I 0 is the intensity of the highest peak) at 2 ⁇ 0.2 of 5.6, 11.1, 13.5, 14.8, 16.2, 17.5, 18.0, 20.1, 20.4, 21.2, 22.2, 24.5, 25.2, 26.3, 27.5, 29.8, 31.1, 32.8 and 36.5 (FIG. 1).
  • a DSC scan of the crystalline tetrahydrate obtained at 5 ° C/min shows an endothermic peak of about 179 J/g which starts at about 100 0 C and reaches its maximum at about 118 ° C , as l o well as an exothermic peak of about 451 J/g which starts at about 203 ° C and reaches its maximum at about 211 ° C (FIG. 2).
  • the actually observed melting point of the crystalline tetrahydrate is around 202 ° C, and the moisture content thereof determined by loss-on-drying test is 8.0 to 9.5% which is within the experimental error range of 8.49% of the theoretical
  • the present invention also covers a partial or heterogenic crystalline form of S-omeprazole strontium or a hydrate thereof.
  • Another preferred embodiment of the present invention provides a partial or heterogenic crystalline anhydrate of S-omeprazole
  • Still another preferred embodiment of the present invention provides a partial or heterogenic crystalline hydrate of S-omeprazole strontium whose XRD spectrum shows a major peak having an 1/I 0 value of 100% at 2 ⁇ 0.2 of 25.2 (FIG. 5).
  • S-omeprazole strontium of formula (I) is also provided in an amorphous form, and its XRD spectrum shows no distinctively characteristic peak (FIG. 7).
  • a DSC scan of the amorphous form obtained at 5 °C/min shows an endothermic peak which starts at about 29 °C and reaches its maximum at about 56 ° C, as well as an exothermic peak which starts at about 183 ° C and reaches its maximum at about 208 0 C (FIG. 8). This suggests that a phase transition occurs at about 196 " C .
  • the amorphous form is observed to decompose at a temperature of about 180 ° C or higher.
  • the inventive S-omeprazole strontium of formula (I) or a hydrate thereof satisfies the pharmaceutically required stability since it can maintain the initial moisture content, purity and crystallinity under a long-term storage condition (25 °C under 60% relative humidity), an accelerated aging condition (40 ° C under 75% relative humidity) or an stressed condition (60 ° C and 75% relative humidity) conducted for 4 weeks or more in a closed state.
  • the crystalline S-omeprazole strontium tetrahydrate (crystalline form A) is non-hygroscopic and it is capable of maintaining its initial moisture content under an exposed condition at 25 to 40 °C and 40 to 90% relative humidity for 2 weeks or more.
  • inventive S-omeprazole strontium of formula (I) or a hydrate thereof may be pharmaceutically preferred in terms of water solubility over other salts of S-omeprazole.
  • it has a water solubility of about 17.6 mg/ml, which is at least 10 times higher than that of
  • S-omeprazole strontium of formula (I) or a hydrate thereof may be prepared by adding strontium hydroxide or another strontium salt to a neutral or basic solution containing
  • the crystalline S-omeprazole strontium tetrahydrate of formula (IV) may be prepared by adding strontium hydroxide to a neutral solution containing S-omeprazole of formula (III), stirring the resulting mixture until precipitates form, and filtering and drying the resulting precipitates by a conventional method:
  • the neutral solution used herein means a solution prepared by dissolving or suspending S-omeprazole in an organic solvent selected from methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, tetrahydrofuran and acetone, preferably, methanol and acetone, or in a mixture of one of said organic solvents and water, preferably, having a mix ratio having a mix ratio of 99:1 to 50:50 (v/v).
  • strontium hydroxide is preferably used in an amount of 0.5 to 0.75 molar equivalent based on S-omeprazole of formula (III).
  • the stirring procedure may be carried out at a temperature ranging from 0 °C to the boiling point of the solvent used for 30 minutes to 24 hours.
  • the crystalline S-omeprazole strontium tetrahydrate may be prepared by adding a reactive strontium salt to a basic solution of S-omeprazole of formula (III) containing a base, stirring the resulting mixture until precipitates form, and filtering and drying the resulting precipitates by a conventional method.
  • the reactive strontium salt may be selected from strontium chloride, strontium bromide, strontium sulfate, strontium nitrate, strontium perchlorate, strontium acetate, strontium carbonate and strontium oxalate, preferably strontium chloride and strontium acetate.
  • the basic solution means a solution prepared by dissolving or suspending S-omeprazole and a base in an organic solvent selected from methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, tetrahydrofuran and acetone, preferably, methanol and acetone or in a mixture of one of said organic solvents and water, preferably, having a mix ratio of 99:1 to 50:50 (v/v).
  • the base may be selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, trimethylamine and triethylamine, preferably sodium hydroxide and potassium hydroxide.
  • the base is preferably used in an amount ranging from 1 to 3 molar equivalents based on 1 mole of S-omeprazole of formula (III) and the amount of the reactive strontium salt is preferably in the range of 0.5 to 0.75 molar equivalent based on the base.
  • the stirring may be conducted at a temperature ranging from 0 ° C to the boiling point of the solvent used for 30 minutes to 24 hours.
  • the neutral or basic solution contains Ig of S-omeprazole of formula (III) in a volume of 1 to 20m£, preferably 3 to lOm-C.
  • S-omeprazole salts having high optical purity can be obtained even when an optically impure S-omeprazole is used as a starting material.
  • the partial or heterogenic crystalline anhydrate of S-omeprazole strontium may be prepared by drying the crystalline S-omeprazole strontium tetrahydrate at 80 to 130 ° C for 30 minutes to 24 hours to dehydrate, if necessary, under a reduced pressure.
  • the partial or heterogenic crystalline hydrate of S-omeprazole strontium may be prepared by suspending such crystalline anhydrate in water, stirring the suspension at room temperature for 1 to 24 hours, and filtering and drying the resultant by a conventional method.
  • the amorphous form of S-omeprazole strontium may be prepared by dissolving the crystalline S-omeprazole strontium tetrahydrate in an organic solvent such as acetone and removing the organic solvent from the resulting solution by evaporation under a reduced pressure or spray drying.
  • the inventive S-omeprazole strontium of formula (I) or a hydrate thereof as mentioned above has a high optical purity of at least 99.0% enantiomeric excess (ee), non-hygroscopicity and good stability against moisture and heat, so that it can be pharmaceutically used for the prevention or treatment of gastric acid-related disorders such as gastroesophageal reflux disease, gastroenteritis and gastric ulcer due to hyperacidity. Accordingly, the present invention provides a pharmaceutical composition comprising the inventive S-omeprazole strontium of formula (I) or a hydrate thereof as an active ingredient.
  • the pharmaceutical composition according to the present invention may be administered via various routes including oral, rectal and injectable application, preferably the oral route.
  • the pharmaceutical composition of the present invention may be in the form of tablets, capsules, pills, and the like, and may be formulated with pharmaceutically acceptable carriers, diluents or excipients.
  • suitable carriers, diluents and excipients are excipients such as starches, sugar and mannitol; filling agents or increasing agents such as calcium phosphate and silica derivatives; binding agents such as cellulose derivatives of carboxymethylcellulose or hydroxypropylcellulose, gelatin, arginic acid salt, and polyvinylpyrrolidone; lubricating agents such as talc, magnesium or calcium stearate, hydrogenated castor oil and solid polyethylene glycol; disintegrants such as povidone, croscarmellose sodium, and crospovidone; and surfactants such as polysorbate, cetyl alcohol and glycerol monostearate.
  • compositions comprising a specific amount of active ingredient, together with or without additives such as said excipients, diluents or additives, may be prepared in accordance with any of the conventional procedures ⁇ see Remington's Pharmaceutical Science, Mack Publishing Company, Easton, Pa., 19 th Edition, 1995).
  • the pharmaceutical composition of the present invention may be prepared by directly filling the inventive S-omeprazole strontium or a hydrate thereof and a pharmaceutically acceptable carrier in vials under a sterile condition, or by filling the amorphous powder obtained by dissolving the inventive S-omeprazole strontium or a hydrate thereof and a pharmaceutically acceptable carrier in sterile water and then freeze-drying in vials, which is dissolved in sterile water to be administered.
  • the pharmaceutical composition for oral administration of the present invention may contain S-omeprazole strontium of formula (I) or a hydrate thereof in an amount ranging from 0.1 to 95% by weight, preferably 1 to 70% by weight based on the total weight of the composition.
  • a typical daily dose of S-omeprazole strontium of formula (I) or a hydrate thereof for a mammalian including human may range from about 0.5 to 500 mg/kg body weight, preferably 5 to 100 mg/kg body weight, and can be administered in a single dose or in divided doses.
  • Example 1 S-Omeprazole (30.Og 5 86.9mmol) having an optical purity of 95% ee was dissolved in 200m£ of methanol, and strontium hydroxide octahydrate (13.8g, 51.9mmol) dissolved in lOOm ⁇ of methanol was slowly added thereto, followed by stirring the mixture at room temperature for 3 hours. The precipitate formed was filtered, washed with lOOm- ⁇ of methanol and dried at 45 " C for 12 hours, to obtain 33.8 g of the title compound (yield: 92%) as an white crystalline powder.
  • the differential scanning calorimeter (DSC) curve obtained at 5 ° C /min of the crystalline S-omeprazole strontium tetrahydrate showed an endothermic peak of 178.9 J/g which starts at
  • Moisture content (Loss-on-Drying Test): 8.7% (calculated for tetrahydrate,
  • Moisture content (Loss-on-Drying Test): 8.9% (calculated for tetrahydrate, 8.49%)
  • Strontium content (EDTA titration): 11.35% (calculated for anhydrate, 11.3%)
  • Potassium hydroxide (5.3g, 94.5mmol) was dissolved in 150m# of water, and S-omeprazole (27.5g, 79.6mmol) having an optical purity of 95% o ee was dissolved therein.
  • strontium chloride hexahydrate (12.7g, 47.8mmol) dissolved in 150m# of methanol was slowly added, and the resulting mixture was stirred at room temperature for 3 hours.
  • the precipitate formed was filtered, washed with a mixture of water (20M) and methanol (8(M) and dried at 45 ° C for 12 hours, to obtain 28.7 g of the title 5 compound (yield: 85%) as an white crystalline powder.
  • Moisture content (Loss-on-Drying Test): 9.0% (calculated for tetrahydrate,
  • Potassium hydroxide (5.3g, 94.5mmol) was dissolved in 15OmU. of water, and S-omeprazole (27.5g, 79.6mmol) having an optical purity of 95% ee was dissolved therein.
  • 150m£ of methanol and strontium acetate (12.7g, 47.8mmol) dissolved in 50m£ of water were slowly added thereto, and the 0 resulting mixture was stirred at room temperature for 3 hours.
  • the precipitate formed was filtered, washed with a mixture of water (2Om-C) and methanol (8Om-E) and dried at 45 ° C for 12 hours, to obtain 28.0 g of the title compound (yield: 83%) as an white crystalline powder.
  • Moisture content (Loss-on-Drying Test): 9.0% (calculated for tetrahydrate,
  • Omerprazole content (HPLC, condition A): 88.5% (calculated for anhydrate, 0 88.7%)
  • Example 7 50g of the inclusion complex of (S)-(-)-binol and S-omeprazole 5 (optical purity: 97.0% ee) obtained in Example 7 was dissolved in 50Om-S of isopropyl acetate, and sodium hydroxide (3.8g, 95.0mmol) dissolved in 150 mi of water was thereto, followed by stirring the resulting mixture at room temperature for 3 hours. After separating isopropyl acetate, the aqueous layer was washed with 20(M of isopropyl acetate. To the basic aqueous 5 layer including S-omeprazole, a strontium chloride hexahydrate (12.6g, 47.5 mmol) dissolved in 150M of methanol was slowly added.
  • Moisture content (Loss-on-Drying Test): 8.8% (calculated for tetrahydrate, 8.49%) 5 Strontium content (EDTA titration): 11.3% (calculated for anhydrate, 11.3%) Omerprazole content (HPLC, condition A): 88.6% (calculated for anhydrate, 88.7%) Optical purity (HPLC, condition B): 99.7% ee
  • Example 2 30.Og of crystalline S-omeprazole strontium tetrahydrate (Crystalline Form A) obtained in Example 1 was dried at 100 ° C for 5 hours, to obtain 27.0 g of the title compound. 5
  • Example 9 obtained in Example 9 was suspended in 150 mi of water and stirred at room temperature for 12 hours. The precipitate formed was filtered and dried at 45 °C for 12 hours, to obtain 16.5 g of the title compound.
  • the result of XRD analysis for the S-omerprazole strontium obtained 5 showed a major peak having an 1/I 0 value of 100% at 2 ⁇ 0.2 of 25.2 (FIG. 5), and DSC curve obtained at 5 °C/min showed an endothermic peak which starts at 37.11 °C and reaches its maximum at 68.09 °C , as well as an exothermic peak which starts at 161.3 ° C and reaches its maximum at 188.81 °C (FIG. 6), which was a partial and heterogenic crystalline hydrate 0 form.
  • Example 2 25.Og of crystalline S-omeprazole strontium tetrahydrate (Crystalline Form A) obtained in Example 1 was dissolved in 250 mi of acetone, and the 5 resulting solution was subjected to solvent-evaporation under a reduced pressure, to obtain 21.O g of the title compound.
  • the result of XRD analysis for the S-omerprazole strontium obtained showed an amorphous form having no distinctively characteristic peak as shown in FIG. 7. 5 Also, as can be seen from FIG. 8, DSC curve of the amorphous form obtained at 5 ° C/min showed an endothermic peak which starts at 29.16°C reaching maximum heat absorption point at 55.88 °C, as well as an exothermic peak which starts at 182.85 ° C reaching its peak at 207.78 ° C in which phase transition occurred at 195.13 °C .
  • Comparative Example 1 The procedure of Comparative Example 1 was repeated except for using S-omeprazole having an optical purity of 90% ee and 80% ee, respectively.
  • the S-omeprazole strontium or a hydrate thereof prepared according to the present invention and the S-omeprazole magnesium trihydrate were each dissolved in deionized water to saturation.
  • the water-solubility of each of the saturated solutions was analyzed by HPLC under the previously described condition A and the amount of each salt hydrate dissolved was measured. The results are shown in Table 3.
  • the solubility of the inventive S-omeprazole strontium and hydrates thereof are at least 10 times higher than that of the known S-omeprazole magnesium trihydrate, which suggests that the inventive strontium salt and hydrates thereof are more suitable for injectable application.
  • the S-omeprazole strontium tetrahydrate prepared according to the present invention was exposed in the naked state at 25 to 40 °C and 40 to 90% relative humidity for a period of over 15 days.
  • the moisture contents of the inventive salt measured by loss-on-drying test at storage time O 5 3, 7 and 15 days are shown in Table 4.
  • the inventive S-omeprazole strontium tetrahydrate was less hygroscopic under a highly humid condition, and its initial moisture content was maintained under a low humidity condition.
  • the S-omeprazole strontium tetrahydrate prepared according to the present invention was stored in the sealed state under a stressed condition of
  • the inventive S-omeprazole strontium tetrahydrate is highly stable as witnessed by the result obtained under the accelerated aging condition.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne le S-omeprazole strontium ou un hydrate dudit composé pour le traitement prophylactique et thérapeutique d'une maladie liée à l'acide gastrique, ledit composé étant de pureté optique, thermostabilité, solubilité et non-hygroscopie élevées. La présente invention concerne également une méthode de synthèse du composé et une préparation pharmaceutique le comprenant.
PCT/KR2006/004369 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant WO2007049914A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2006306906A AU2006306906B2 (en) 2005-10-26 2006-10-25 S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
BRPI0617879-0A BRPI0617879A2 (pt) 2005-10-26 2006-10-25 estrÈncio de s-omeprazol ou hidrato deste, método para preparar o mesmo, e composição farmacêutica compreendendo o mesmo
CN2006800396089A CN101296921B (zh) 2005-10-26 2006-10-25 S-奥美拉唑锶水合物，它的制备方法，和包含它的药物组合物
CA2626085A CA2626085C (fr) 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant
NZ568412A NZ568412A (en) 2005-10-26 2006-10-25 S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same.
JP2008537592A JP5017274B2 (ja) 2005-10-26 2006-10-25 Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
IL190709A IL190709A (en) 2005-10-26 2008-04-08 5-Omprazole Strontium or Hydrate, Methods of Preparation and Pharmaceutical Preparations Containing Them
NO20082358A NO20082358L (no) 2005-10-26 2008-05-23 S-omeprazol-stronsium eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat omfattende disse

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2005-0101059 2005-10-26
KR20050101059 2005-10-26
KR2006000760 2006-03-06
KRPCT/KR2006/000760 2006-03-06

Publications (1)

Publication Number Publication Date
WO2007049914A1 true WO2007049914A1 (fr) 2007-05-03

Family

ID=37967988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/004369 WO2007049914A1 (fr) 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant

Country Status (8)

Country Link
JP (1) JP5017274B2 (fr)
AU (1) AU2006306906B2 (fr)
CA (1) CA2626085C (fr)
IL (1) IL190709A (fr)
MY (1) MY140986A (fr)
NO (1) NO20082358L (fr)
RU (1) RU2372345C1 (fr)
WO (1) WO2007049914A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CN116102538A (zh) * 2023-01-29 2023-05-12 山东省分析测试中心 一种转晶制备三水合艾司奥美拉唑镁的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099182A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de zinc de (s)-omeprazole
WO2005011692A1 (fr) * 2003-07-23 2005-02-10 Altana Pharma Ag Sels alcalins d'inhibiteurs de la pompe a protons
WO2006120520A1 (fr) * 2005-05-06 2006-11-16 Glenmark Pharmaceuticals Limited Sel de strontium d'esomeprazole, procede de preparation de ce sel et compositions pharmaceutiques le contenant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US7243788B2 (en) * 2003-10-22 2007-07-17 Kimberly-Clark Worldwide, Inc. Package for segregating and mixing substances

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099182A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de zinc de (s)-omeprazole
WO2005011692A1 (fr) * 2003-07-23 2005-02-10 Altana Pharma Ag Sels alcalins d'inhibiteurs de la pompe a protons
WO2006120520A1 (fr) * 2005-05-06 2006-11-16 Glenmark Pharmaceuticals Limited Sel de strontium d'esomeprazole, procede de preparation de ce sel et compositions pharmaceutiques le contenant

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US8106076B2 (en) 2005-10-26 2012-01-31 Hanmi Holdings Co., Ltd. Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US8513426B2 (en) 2005-10-26 2013-08-20 Hanmi Science Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US8586752B1 (en) 2005-10-26 2013-11-19 Hanmi Science Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CN116102538A (zh) * 2023-01-29 2023-05-12 山东省分析测试中心 一种转晶制备三水合艾司奥美拉唑镁的方法

Also Published As

Publication number Publication date
AU2006306906B2 (en) 2010-02-04
IL190709A0 (en) 2008-11-03
JP5017274B2 (ja) 2012-09-05
JP2009513625A (ja) 2009-04-02
NO20082358L (no) 2008-07-25
RU2372345C1 (ru) 2009-11-10
CA2626085C (fr) 2011-12-06
MY140986A (en) 2010-02-12
AU2006306906A1 (en) 2007-05-03
IL190709A (en) 2012-03-29
CA2626085A1 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
US8586752B1 (en) Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US7928114B2 (en) Crystalline erlotinib
SK16372002A3 (sk) Zolpidem hemitartrát
EP2144896A1 (fr) Hydrate de sel métallique de bepotastine cristallin, procédé de préparation afférent et composition pharmaceutique renfermant ledit hydrate
AU2006306906B2 (en) S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
CA2366391C (fr) Aspartate d'amlodipine
JP2011236210A (ja) オメプラゾールのエナンチオマーのマグネシウム四水和物塩を調製するための前駆体相およびその使用
EP3398946A1 (fr) Sel de dérivé de morpholine et sa forme cristalline, et procédé de préparation, composition pharmaceutique et utilisation de ce dernier
JP5393028B2 (ja) Ｓ−テナトプラゾールナトリウム塩一水和物及び治療におけるその使用
EP1485373A1 (fr) Procede de stabilisation de lansoprazole
JP2014518236A (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
CZ12613U1 (cs) Chemická sloučenina amlodipinaspartát a farmaceutický prostředek
KR20130063762A (ko) 신규 에스라베프라졸, 이의 알칼리금속 및 알칼리토금속염 및 이의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680039608.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PI 20081014

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 190709

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006306906

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2626085

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12008500918

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005259

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008537592

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 568412

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4308/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008120703

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06799424

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: PI0617879

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080425

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载